IJCRR - Vol 06 Issue 13, July, 2014
CLINICAL STUDY OF MUTLAZIMA QABL HAIZ (PREMENSTRUAL SYNDROME) AND ITS MANAGEMENT WITH UNANI FORMULATION - A RANDOMIZED CONTROLLED TRIAL
Author: Hafeeza, Wasia Naveed, Ismath Shameem, K. Tabassum
Background and Objectives: Mutlazima Qabl Haiz (Premenstrual Syndrome) is a group of menstruation related cyclical disorder manifested by emotional and physical symptoms in the second half of the menstrual cycle, which subsides after the beginning of menstruation. During the reproductive years, 80-90% of menstruating women experience symptoms like breast pain, bloating, acne, constipation, mood swings, irritability and depression that fore warns them of impending menstruation. The objective of the study was to evaluate the efficacy of Tukhme Sambhalu (Vitexagnuscastus) and Arq Pudina (Menthapiperita) in the management of Mutlazima Qabl Haiz. Methods: A single blind, randomized placebo controlled study was carried out in Gynaec OPD of the Institute?s Hospital, Bangalore. Patients were randomly allocated to test (n=30) and control (n=30) groups. Patients in the age group of 13-40 years with regular menstrual cycle were included in the study irrespective of marital status and parity. In test group, Tukhme Sambhalu1 gm and Arq Pudina 36 ml were administered orally twice daily, 10 days prior to menstruation in every cycle for 3 consecutive months. In control group placebo was given for the same duration. Severity of Premenstrual Syndrome was assessed by Premenstrual Tension Syndrome Scale and reduction in the Premenstrual Tension Syndrome Scale score was noted in each cycle. The data were analyzed using Analysis of variance - one way with Turkey Kramer Multiple pair comparison test and Premenstrual Tension Syndrome Scale scores of the two groups were compared by Chi Square test. Results: In test group, 70% patients were cured while 16.66% and 10% were relieved and partially relieved respectively, while 3.33% patients showed no response. In control group, the cured, relieved, and partially relieved patients were 23.33%, 23.33% and 20% respectively where as 33.33% patients showed no response. Significant reduction in the Premenstrual Tension Syndrome Scale scores was observed in test group than compared to control group (p<0.01). Interpretation and Conclusion: The test drugs, Tukhme Sambhaluand Arq Pudina were effective in reducing the somatic and psychological symptoms of Mutlazima Qabl Haizas compared to placebo.vvv
Keywords: Premenstrual Syndrome; Premenstrual Tension Syndrome Scale; Vitexagnuscastus; Menthapiperita.
Hafeeza, Wasia Naveed, Ismath Shameem, K. Tabassum. CLINICAL STUDY OF MUTLAZIMA QABL HAIZ (PREMENSTRUAL SYNDROME) AND ITS MANAGEMENT WITH UNANI FORMULATION - A RANDOMIZED CONTROLLED TRIAL International Journal of Current Research and Review. Vol 06 Issue 13, July, 51-57
1. Chanana C, Rehman SM. Premenstrual syndrome. Obs Gynae Today 2006; 9 (8): 452 4.
2. Johnson SR. Premenstrual Syndrome, Premenstrual Dysphoric Disorder and Beyond: A Clinical Primer for Practitioners. ObstetGynaecol 2004; 104 (4):845 59.
3. Sternfeld B, Swindle R, Chawla A, Long S, Kennedy S. Severity of Premenstrual Symptoms in a Health Maintenance Organization Population. ObstetGynaecol 2002;99:1014 24.
4. www.languagesource.com/acatolog/Arabic_Tr anslation_Software_Arabic_Al_Wafi.html. cited on27.11.06
5. Anonymous. The Unified Medical Dictionary. Eng Ara Fren.3 rd ed. Switzerland: Council of Arab ministers of health; 1983:642.
6. IbnSina. Al QanoonFilTib. Vol II. (Urdu Translation by Kantori GH). New Delhi: IdaraeKitabusShifa; 1981: 331.
7. Kapur A. Use of Evening Primrose Oil in Premenstrual Syndrome. ObstetGynaecol 2001; 6 (11):690 695.
8. Kessel B. Premenstrual Syndrome: Advances in Diagnosis and Treatment. ObstetGynaecol of North America 2000;27(3): 625 639.
9. http://www.webmd.Com/women/pharmacist 11/herbal treatments for pms. Cited on06/12/2013.
10. Copeland LJ, Jarrell JF, McGregor JA. Textbook of Gynaecology. Philadelphia: WB Saunders Company; 1993: 403 413.
11. http://www.betterhealth.vic.gov.au/bhcv2/bhc articles.nsf/pages/premenstrual_syndrome. Cited on 04.12.2013.
12. Zulkifle MD. Physiochemical Basis of Temperament. Thesis submitted to the Department of Kulliyat, AKTC, U. P: Aligarh, AMU; 1993.
13. Kabeeruddin. BayazeKabir. VolII. Hyderabad:Hikmat Book Depot;1921:96.
14. http://altmedicine.about.com/cs/womenshealth /a/PMS.htm. Cited on 07.12.2013.
15. Kabeeruddin M. MaghzanulMufradat. New Delhi: Aejaz Publication; YNM: 170, 171, 358, 359.
16. Critchlow DG, Bond AJ, Wingrove J. Mood Disorder: History and Personality Assessment in Premenstrual Dysphoric Disorder. J clinPsychiatry 2001; 66(9): 688 93.
17. Haskett SM, Caroll BJ. Premenstrual Tension Syndrome: The Development of Research Diagnostic Criteria and New Rating Scales: Acta Psychiatry Scand 1980; 62(2): 177 90.
18. Steiner M, Steiner DL, Stein Berg S et.al. TheMeasurement of Premenstrual Mood Symptoms. J Affect Disord 1999; 53(3): 269 273.
19. Ann Le´vesque, Marc Letellier, Paul W. Dillon, and Andrew Gran. Analytical Performance of Bayer ImmunoEstradioland Progesterone Assays. Clinical Chemistry 1997; 43 (9): 1601–9.
20. Melmed S, Kleinberg D. Anterior pituitary. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds.Williams Textbook of Endocrinology. 11 th ed. Philadelphia, PA: Saunders Elsevier; 2008: Chap 8.
21. Johnson SR. The Epidemiology and Social Impact of Premenstrual Symptoms. linObstetGynaecol 1987; 30 (2): 367 76.
22. Lawrence N. Adolescent Health Care: A Practical Guide. 5 th ed. Lippincott: Williams and Wilkins; 2008: 678 9.
23. Freeman EW, Sondheimer S, Wein PJ, Baum, Rickets K. Evaluating Premenstrual Symptoms in Medical Practice. ObstetGynaecol 1985; 65 (4): 500 5.
24. Schellenberg R. Treatment for Premenstrual Syndrome with AgnusCastus Fruit Extract: Prospective, Randomized, Placebo Controlled Study. BMJ 2001; 332: 134 7.
25. Girman A, Lee R, Kligler B. An Integrative Medicine Approach to Premenstrual Syndrome. AmJObstetGynecol 2003; 188(5):